ACTR-50. MARIZOMIB (MRZ) WITH BEVACIZUMAB (BEV) IN WHO GRADE IV MALIGNANT GLIOMA (G4 MG): FULL ENROLLMENT RESULTS FROM THE PHASE 1, MULTICENTER, OPEN-LABEL STUDY

  • Bota D
  • Desjardins A
  • Mason W
  • et al.
N/ACitations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

MRZ is an irreversible, brain-penetrant, pan-proteasome inhibitor (PI) with anti-MG efficacy preclinically in vitro and in vivo. The safety, pharmocokinetics, and activity of MRZ+BEV is evaluated in BEV-naive G4 MG patients (pts) in first or second relapse (no prior anti-angiogenic or PI therapy), in a 3+3 dose-escalation (MRZ 0.55 (6 pts), 0.7 (3 pts), and 0.8 mg/m2 (3 pts)) followed by dose-expansion (0.8 mg/m2, 24 pts). Treatments administered IV, 28-day cycles: MRZ (10 min) days 1, 8, & 15; BEV (10 mg/kg) days 1 & 15. Tumor response assessed every other cycle by RANO criteria; MRZ and BEV pharmacokinetics, and proteasome inhibition in circulating blood cells also evaluated. Data reported as of 17 May 2016; median age 55 yrs (range 27-76 yrs), 64% male, Karnofsky score >=70. Duration of dosing 0.5-11.6 months to date; treatment ongoing in 16 pts. Study treatment-related Grade >=3 AEs: fatigue, headache, hypertension, hallucination, confusional state, ataxia; one Grade 4 SAE (appendicitis perforated, not related to study treatment), one Grade 5 SAE (intracranial hemorrhage, BEV-related). One pt (cohort 1) had DLT (fatigue); no other DLTs occurred. N=36 for the intent-to-treat population; 30 pts efficacy evaluable by RANO criteria. Overall response (>= partial response, PR) 39% (14/36, including 5 with complete target lesion response and 2 unconfirmed PRs); 11 stable disease, 5 progressive disease. PFS 6-months is 39%; median OS not yet reached. MGMT status known for 15 of 36 pts; 14 unmethylated (uMGMT), 1 methylated. Seven of 14 uMGMT pts achieved >=PR; 49% PFS 6-months in uMGMT subgroup. Preliminary activity in uMGMT subgroup suggests therapeutic advantage provided by brain-penetrant PI in comparison with BEV single agent (Taal et al., 2014). MRZ+BEV combination is well tolerated with promising early signs of efficacy in recurrent G4 MG pts.

Cite

CITATION STYLE

APA

Bota, D., Desjardins, A., Mason, W., Fine, H., Kesari, S., Reich, S. D., … Trikha, M. (2016). ACTR-50. MARIZOMIB (MRZ) WITH BEVACIZUMAB (BEV) IN WHO GRADE IV MALIGNANT GLIOMA (G4 MG): FULL ENROLLMENT RESULTS FROM THE PHASE 1, MULTICENTER, OPEN-LABEL STUDY. Neuro-Oncology, 18(suppl_6), vi13–vi13. https://doi.org/10.1093/neuonc/now212.048

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free